









Markets
/
Stocks
/
nasdaq-chek
/

Check Cap Ltd

CHEK

1.335USD

+0.035+2.69%

Market hours （ET）Quotes delayed by 15 min

7.81MMarket Cap

LossP/E TTM



Check Cap Ltd

1.335

+0.035+2.69%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Check Cap Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Check Cap Ltd's Score

Industry at a Glance

Industry Ranking

298 / 501

Overall Ranking

559 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Check Cap Ltd Highlights

StrengthsRisks

Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.37, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 129.83K shares, decreasing 29.02% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.12.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Check Cap Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 8.83, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.37, which is -28.15% below the recent high of -0.27 and -2696.57% above the recent low of -10.34.

Score

Industry at a Glance

Previous score

8.83

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 298/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.60, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.19 and the support level at 1.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.62

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.120

Sell

RSI(14)

35.612

Neutral

STOCH(KDJ)(9,3,3)

3.449

Oversold

ATR(14)

0.145

Low Volatility

CCI(14)

-115.645

Sell

Williams %R

99.000

Oversold

TRIX(12,20)

-1.259

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.374

Sell

MA10

1.462

Sell

MA20

1.674

Sell

MA50

1.620

Sell

MA100

1.172

Buy

MA200

1.006

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

EquityLine Alternate Assets GP Inc

762.72K

Ramanathan (Vijay)

360.00K

Symetryx Corp

338.63K

Citadel Advisors LLC

31.22K

+49.70%

Susquehanna International Group, LLP

27.58K

BNP Paribas Securities Corp. North America

20.14K

+1.51%

Virtu Americas LLC

11.76K

Two Sigma Investments, LP

11.38K

-0.87%

Dimensional Fund Advisors, L.P.

8.96K

UBS Financial Services, Inc.

5.94K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.